معرفی
Ying Qing Chen is a Professor of Medicine at the Stanford Prevention Research Center, part of the Department of Medicine at Stanford University. Additionally, she holds an Affiliate Professor position in Biostatistics. Her roles include serving as Director of the Palo Alto Veteran Affairs Cooperative Studies Coordinating Center since 2021.
Dr. Chen earned her BS in Mathematics from Peking University (1992) and her PhD in Biostatistics from Johns Hopkins University (1999). Her research focuses on statistical methodologies for HIV/AIDS prevention, including biomarkers, clinical trial design, epidemiological methods, and survival analysis. She also contributes to studies on vaccine effectiveness, adherence to antiretroviral treatments, and the intersection of social stigma with healthcare access in high-risk populations.
Her work spans multinational collaborations, such as the HPTN 052, 069/ACTG 5305, and 075 trials, and she leads projects funded by NIH and industry partners (e.g., Sinovac Biotech). Key areas of expertise include evaluating combination prevention strategies, developing statistical surrogacy measures, and analyzing longitudinal clinical data to inform public health policies.
- Projects:
- Co-PI for the Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT) study (NIH/NIAID U01 AI163090-01, 2021-Present)
- PI for Research on Global Vaccine Application and Trends (Sinovac Biotech, 2021-Present)
- PI/MPI for Ganciclovir to Prevent Cytomegalovirus Reactivation (NIH/NHLBI U24 HL147012, 2020-Present)
Dr. Chen’s scientific contributions have been recognized with the Fellowship of the American Statistical Association (2018). She teaches courses such as Introduction to Clinical Trials: Design, Conduct, and Analysis (CHPR 211) and supervises thesis writing through Community Health and Prevention Research Master's Thesis Writing (CHPR 399).
Her research emphasizes improving HIV prevention outcomes, addressing challenges in adherence and combination therapies, and leveraging statistical innovations to enhance vaccine efficacy assessments. She has also demonstrated expertise in handling complex longitudinal datasets and conducting feasibility studies for at-risk populations in sub-Saharan Africa.
